Skip to main content

Exelixis Posts Q3 Revenue Rise

SAN FRANCISCO, Nov. 13 - Exelixis on Tuesday posted third-quarter revenues of $11.9 million versus $6.1 for the same quarter a year ago, the company announced.

 

The South San Francisco-based company attributed the revenue rise to new collaborations with Bristol-Myers Squibb and Protein Design Labs.

 

Exelixis reported a net loss of $13.4 million, or 28 cents per share for the third quarter of 2001, compared to a net loss of $5.5 million, or 13 cents per share for the third quarter of 2000.

 

General and administrative expenses for the period increased to $4.8 million from $2.6 million for the year-ago period. Research and development rose to $21.3 million from $11.1 million for the third quarter of 2000.

 

"The third quarter was highly productive for Exelixis, both in establishing key strategic partnerships with leading companies such as Bristol-Myers Squibb and Elan and in moving our internal programs forward aggressively," George Scangos, CEO of Exelixis, said in a statement. "We remain on track to announce our first lead compound by year end."

 

The company reported $132.3 million in cash, cash equivalents and short-term investments as of September 30, 2001.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.